Bayer HealthCare - Articles and news items

Relocating the EMA: An open letter from EFPIA and Pharma Heads of Research

Industry news / 16 May 2017 / European Federation of Pharmaceutical Industries and Associations (EFPIA)

The EMA is a world class regulator, whose scientific recommendations are a vital element of the ongoing effort to provide EU citizens with quality medicines

Stivarga

FDA expands approved use of Bayer’s liver cancer treatment

Industry news / 2 May 2017 / Niamh Marriott, Junior Editor

The FDA has expanded the approved use of Bayer’s Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma…

Alliance management organisational development: A Bayer perspective

Blog, Z Homepage promo / 4 April 2017 / Christoph Huwe, Strategic Alliance Manager Therapeutics at Bayer Pharmaceuticals, Global External Innovation & Alliances

Ahead of the 7th Annual Strategic Alliance Management for Pharma conference, we spoke with Bayer’s Christoph Huwe about the organisational development of alliance management…

Nanobiotix appoints Oncology industry veteran as Chief Operating Officer

Industry news / 7 February 2017 / Niamh Marriott, Digital Editor

Nanobiotix, a late clinical-stage nanomedicine company, announced the appointment of Alain Dostie, a senior executive from the pharmaceutical industry, as its Chief Operating Officer. Mr Dostie will lead Nanobiotix’s operations, including development, manufacturing, market access and sales, for their lead product NBTXR3, which could obtain a CE Mark approval in 2017. Previously, Mr Dostie was […]

The Top 21…wealthiest pharma companies

Blog, Z Homepage promo / 6 February 2017 / Niamh Marriott, Digital Editor

Find out who made it to the top of our list of richest pharma companies…

FDA grants priority review for Bayer’s liver cancer treatment

Industry news / 4 January 2017 / Niamh Louise Marriott, Digital Editor

The application is based on data from the placebo-controlled Phase III trial which investigated the drug as a second line treatment…

NICE recommends Bayer’s prostate cancer drug for routine NHS use

Industry news / 2 September 2016 / Niamh Louise Marriott, Digital Content Producer

NICE has today issued draft final guidance recommending radium-223 dichloride (Xofigo, Bayer) as an option for treating prostate cancer…

NICE says Bayer’s liver cancer drug is not cost-effective

Industry news / 24 August 2016 / The National Institute for Health and Care Excellence (NICE)

NICE originally published guidance in 2010 which said that sorafenib was not cost effective but it was then made available through the CDF. NICE is reconsidering sorafenib as part of its programme to appraise drugs that are currently available…

Regorafenib increases overall survival in hepatocellular carcinoma study

Industry news / 29 June 2016 / Victoria White, Digital Content Producer

Results from the Phase III RESORCE trial investigating Bayer’s regorafenib in patients with unresectable hepatocellular carcinoma have been announced…

Leaving EU could be a setback for Life Sciences in the UK

Blog / 8 June 2016 / Dr Alexander Moscho, Bayer UK & Ireland CEO

In this opinion piece, Dr Alexander Moscho, Bayer UK & Ireland CEO, says a vote to leave the EU will deter investment and make it harder for patients to access new medicines…

Bayer and Orion expand BAY-1841788 programme in prostate cancer

Industry news / 3 June 2016 / Victoria White, Digital Content Producer

The Phase III study ARASENS will evaluate BAY-1841788 in men with newly diagnosed metastatic hormone-sensitive prostate cancer…

Bayer terminates its Phase II riociguat PH-IIP trial

Industry news / 13 May 2016 / Victoria White, Digital Content Producer

Reviewing data from the study, the DMC observed that patients receiving riociguat were at a possible increased risk for death and other serious adverse events…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+